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Abstract Structure determination of integral membrane pro-
teins requires milligram amounts of puri¢ed, functional protein
on a regular basis. Here, we describe a protocol for the puri¢-
cation of a G protein-coupled neurotensin receptor fusion pro-
tein at the 3-mg or 10-mg level using immobilized metal a⁄nity
chromatography and a neurotensin column in a fully automated
mode. Fermentation at a 200-l scale of Escherichia coli express-
ing functional receptors provides the material needed to feed
into the puri¢cation routine. Constructs with tobacco etch virus
protease recognition sites at either end of the receptor allow the
isolation of neurotensin receptor devoid of its fusion partners.
The presented expression and puri¢cation procedures are simple
and robust, and provide the basis for crystallization experiments
of receptors on a routine basis.
) 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
G protein-coupled receptors (GPCRs) are integral mem-
brane proteins involved in important physiological processes,
including cell-to-cell communication, mediation of hormonal
activity and sensory transduction (for reviews see [1,2]).
About 1000 GPCRs have been identi¢ed, 300^400 of which
are found throughout the body binding endogenous ligands
(the remainder are chemosensory GPCRs for odors, phero-
mones or taste) [3]. Many of them have been implicated as
major therapeutic routes to the treatment of human diseases.
Despite the striking clinical relevance of GPCRs, only one
high-resolution structure (rhodopsin) is known [4,5]. One con-
tributing factor to the structure determination of rhodopsin
was its availability in large quantities from natural sources. In
contrast, recombinant overexpression followed by e⁄cient pu-
ri¢cation methods are needed for GPCRs that occur naturally
at low levels [6] (see also Biochim. Biophys. Acta, vol. 1610,
special issue on Overexpression of Integral Membrane Pro-
teins).
Neurotensin (NT) is a 13-amino acid peptide that is in-
volved in a variety of neuromodulatory functions in the cen-
tral and peripheral nervous system [7,8]. NT binds to its re-
ceptors NTS1 and NTS2 [9^12]. The levocabastine-insensitive
neurotensin type I receptor (NTS1) [10^12] interacts with the
agonist NT with high a⁄nity. Similar observations were made
for the N-terminally truncated form of rat NTS1 when ex-
pressed as a maltose-binding protein (MBP) fusion in Esche-
richia coli [13,14] and puri¢ed in the presence of detergents
[14,15].
Crystallization and other applications such as nuclear mag-
netic resonance (see [16,17,28,29]) require milligram quantities
of functional GPCRs. Only a few receptors have been puri¢ed
in such quantities (see [18^22,30]). Large-scale puri¢cation
schemes must be simple and robust to give reproducible re-
sults on a regular basis. Here, we report the puri¢cation of a
G protein-coupled neurotensin receptor fusion protein at the
3-mg or 10-mg level using two successive a⁄nity columns in a
fully automated mode.
2. Materials and methods
2.1. Expression of NTS1 fusion proteins in shake £asks
The NTS1 fusion protein MBP-rT43NTR-TrxA-H10 (NTS1^624)
consists of the E. coli MBP (Lys1 to Thr366), followed by Gly-Ser, the
N-terminally truncated rat NT type I receptor NTS1 (rT43NTR,
Thr43 to Tyr424) [11], three Ala residues, the E. coli thioredoxin
(TrxA, Ser2 to Ala109), Gly-Thr and a decahistidine tag (H10) [23].
The fusion protein MBP-N10-Tev-rT43NTR-N5G3S-Tev-G3S-TrxA-
H10 (NTS1^1023) contains two tobacco etch virus (Tev) protease
recognition sites [24,25] surrounding rT43NTR, with Gly-Ser-Asn10-
Glu-Asn-Leu-Tyr-Phe-Gln-Ser-Gly-Ser between MBP and rT43NTR,
and Ala3-Asn5-Gly3-Ser-Glu-Asn-Leu-Tyr-Phe-Gln-Ser-Gly3-Ser-Glu-
Phe between rT43NTR and TrxA-H10 [17]. In the fusion protein
MBP-N10-Tev-rT43NTR-CH2-N5G3S-G3S-TrxA-H10 (NTS1^1233),
the C-terminus of rT43NTR is changed from Glu421-Thr-Leu-Tyr424
to Glu421-Asn-Leu-Tyr-Phe-Gln-Ser (to constitute a Tev protease rec-
ognition site), followed by Asn5-Gly3-Ser-Gly3-Ser-Glu-Phe and
TrxA-H10. Derivatives of the expression vector pRG/III-hs-MBP
[14] were used for the production of functional, membrane-inserted
receptors in E. coli DH5K. Cells were grown in 750 ml of double-
strength TY medium (BIO 101 systems Q-Biogene) containing ampi-
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cillin (67 Wg/ml) and glucose (0.2% w/v) in ba¥ed 2-l £asks at 37‡C to
an OD600 of 0.5. After induction with 0.25 mM isopropyl-L-thioga-
lactoside (IPTG), the temperature was decreased to 22‡C. The cells
were harvested about 40 h later, frozen in liquid nitrogen, and stored
at 385‡C [14].
2.2. Large-scale fermentation
Two hundred liters of double-strength TY medium (Difco) contain-
ing ampicillin and glucose (see above) in a 300-l working volume
fermenter (New Brunswick Scienti¢c) were inoculated with 200 ml
of an overnight culture grown at 37‡C. Cells were grown at 37‡C to
an OD600 of 0.5 with constant stirring (200 rpm) and air supply of
1 vvm (volume per volume per minute). After induction with 0.25 mM
IPTG, the temperature was decreased to 22‡C. The cells were har-
vested about 40 h later using a continuous £ow centrifuge (Sharples
As 16P) at a £ow rate of 100 l/h, frozen in liquid nitrogen, and stored
at 385‡C.
2.3. Automated large-scale puri¢cation of NTS1 fusion proteins
2.3.1. Reagents and bu¡ers. Cholesteryl hemisuccinate Tris salt
(CHS), and the detergents n-dodecyl-L-D-maltoside (LM) and 3-
[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS)
were from Anatrace (Maumee, OH, USA). Stock solutions (6%
CHAPS/0.12% CHS and 10% LM) were made fresh prior to each
puri¢cation. Protease inhibitor stock solutions were made to 70 mg/
ml (phenylmethylsulfonyl £uoride), 1 mg/ml (leupeptin) and 1.4 mg/ml
(pepstatin A). The following bu¡ers were used [15]: 2Usolubilization
bu¡er: 100 mM Tris^HCl pH 7.4, 60% glycerol, 400 mM NaCl; NiA
bu¡er: 50 mM Tris^HCl pH 7.4, 30% glycerol, 50 mM imidazole, 200
mM NaCl, 0.5% CHAPS/0.1% CHS, 0.1% LM; NiB bu¡er: NiA with
200 mM imidazole; NT0 bu¡er: 50 mM Tris^HCl pH 7.4, 30% glyc-
erol, 1 mM EDTA, 0.5% CHAPS/0.1% CHS, 0.1% LM; NT200 bu¡-
er: NT0 with 200 mM NaCl; NT1K bu¡er: NT0 with 1 M NaCl; A3
bu¡er: 50 mM Tris^HCl pH 7.4, 1 mM EDTA, 1 M NaCl; NT
column storage bu¡er B3: 50 mM Tris^HCl pH 7.4, 1 mM EDTA,
3 mM NaN3.
2.3.2. Solubilization. One hundred grams (250 g) of cells were ho-
mogenized in 250 ml (500 ml) of 2Usolubilization bu¡er using a
Waring blender for 3^5 min. The following steps were carried out
at 4‡C or on ice. After addition of 250 Wl (500 Wl) of each protease
inhibitor, 2.5 ml (5 ml) of a 1 M MgCl2 solution and 200 Wl (300 Wl)
of DNase I stock (Sigma D-4527, 10 mg/ml), 50 ml (100 ml) of each
detergent stock solution were added dropwise with gentle stirring. The
mixture was sonicated for 13 min (33 min) (Misonix sonicator 3000,
1/2 inch £at tip, level 4, 1 s on, 2 s o¡). The volume was then adjusted
to 500 ml (1 l) with H2O. 250 Wl (500 Wl) of each protease inhibitor
were added, and the mixture was stirred for a further 30 min. Cell
debris was removed by centrifugation (Beckman 45 Ti rotor, 45 000
rpm, 1 h). Imidazole (2 M stock solution, adjusted to pH 7.4) was
added to the supernatant to give a ¢nal concentration of 50 mM [23].
The sample was passed through a 0.2-Wm ¢lter (Stericup, Millipore)
and then used for puri¢cation by immobilized metal a⁄nity chroma-
tography.
2.3.3. Automated puri¢cation of NTS1 fusion proteins. A Puri¢er
P100 system (Amersham Biosciences) was equipped with a sample
valve (bu¡er line S1 with air sensor Air-912 for sample loading, and
S8 for rinsing the sample pump with bu¡er NiA), sample pump P950,
injection valve (with the sample pump outlet connected to port 2, and
port 3 connected to port 6), column valves, outlet valve, fraction
collector Frac950, bu¡er valve A1 (with bu¡er lines A11 for H2O,
A12 for bu¡er NT0, A13 for bu¡er NT1K, A16 for bu¡er B3, A17 for
bu¡er A3, A18 for 20% ethanol) connected to bu¡er line A1, bu¡er
line A2 for NiA bu¡er, bu¡er line B1 for NiB bu¡er, and bu¡er valve
B2 (with bu¡er lines B21 for H2O, B22 with air sensor Air-912 for
loading of the Ni-NTA eluate onto the NT column, B27 for 20%
ethanol, B28 for NT200 bu¡er) connected to bu¡er line B2 (Fig. 1).
Te£on tubing (i.d. 1.6 mm) was used as bu¡er inlet lines, whereas
Tefzel tubing (i.d. 0.75 mm) was used as the air sensor inlet lines. A
50-ml or 100-ml Ni-NTA Super£ow (Qiagen) column (XK50, Amer-
sham Biosciences) and a 10-ml or 20-ml NT column [14,15] (XK26)
were used for the puri¢cation of NTS1 fusion proteins at the 3-mg or
10-mg level, respectively. The following details refer to a 10-mg puri-
¢cation. Brie£y, solubilized receptors (V960 ml) were passed through
line S1 by an external sample pump onto the Ni-NTA column at a
£ow rate of 2 ml/min. An air sensor detected the end of loading. After
extensive washing of the Ni-NTA column with 1500 ml of bu¡er NiA
using system pump A, bound receptor fusion protein was eluted in the
presence of 200 mM imidazole (system pump B) at 2 ml/min, and
collected (line F3) into a vessel which contained 1 ml of bu¡er
NT200, into which line B22 was submersed. To reduce the NaCl
and imidazole concentration from 200 mM to 70 mM to allow bind-
ing of NTS1 to the NT column, the Ni-NTA column eluate (line B22,
35% B) was diluted with NT0 bu¡er (line A12) using the system
pumps, and passed onto the NT column at 0.4 ml/min. Again, an
air sensor detected the end of loading. After washing of the NT
column, NTS1 fusion proteins were eluted with NT1K bu¡er and
collected. The step-by-step protocols for the automated column equi-
librations and puri¢cation of NTS1 fusion proteins at the 3-mg or 10-
mg level are available upon request.
2.4. Processing of NTS1 fusion proteins by Tev protease
2.4.1. Expression and puri¢cation of Tev protease. Intracellular ex-
pression as MBP fusion and in vivo autoprocessing of the Tev pro-
tease mutant S219V was done as described using the strain BL21-RIL
pRK793 [26]. Cells were broken with a French press (1 passage at
1200 psi), and the histidine-tagged Tev protease was puri¢ed by Ni-
NTA chromatography (column bu¡er A: 50 mM NaPi pH 8.0, 100
mM NaCl, 10% glycerol, 25 mM imidazole; elution bu¡er B: bu¡er A
with 200 mM imidazole). The Ni-NTA column eluate containing the
His-Tev(S219V)-Arg protease was pooled, diluted 1:1 with glycerol,
frozen in liquid nitrogen, and stored at 320‡C. The protein concen-
tration was 1 mg/ml.
2.4.2. Cleavage of NTS1 fusion proteins by Tev protease. To de-
termine the amount of His-Tev(S219V)-Arg protease necessary for
complete processing of NTS1 fusion proteins, receptors (NT column
eluate, in NT1K bu¡er) were incubated at 4‡C for V15 h with in-
creasing concentrations of Tev protease in the presence of 1 mM
dithiothreitol (data not shown). Complete cleavage of NTS1 fusion
proteins was obtained at a ratio of 1:1 (mol/mol).
2.4.3. Puri¢cation of rT43NTR by gel ¢ltration. Puri¢ed fusion
protein NTS1^1233 (5.4 mg) was incubated with an equimolar
amount of Tev protease in a total of 8 ml at 4‡C overnight. The
mixture was concentrated in a Centriprep-50 device (Millipore) to
3 ml, and applied to a HiLoad 16/60 Superdex 200 prep grade column
(Amersham Biosciences) equilibrated with GF bu¡er (50 mM Tris^
HCl pH 7.4, 15% glycerol, 1 mM EDTA, 1 M NaCl, 0.5% CHAPS/
0.1% CHS, 0.1% LM). Proteins were separated at a £ow rate of 0.4
ml/min, and 1-ml fractions were collected.
2.5. Protein and ligand-binding analysis
The protein content was measured according to the method of
Scha¡ner and Weissmann [27] with bovine serum albumin as the stan-
dard. Speci¢c agonist binding was determined at a [3H]NT (Perkin-
Elmer) concentration of 2 nM in assay bu¡er (50 mM Tris^HCl pH
7.4, 1 mM EDTA, 0.1% bovine serum albumin, 0.004% bacitracin).
Ligand-binding analysis with intact cells [13,14] was carried out in a
volume of 0.5 ml for 4 h on ice. Separation of bound from free ligand
was achieved by rapid ¢ltration through GF/B glass ¢ber ¢lters
(Whatman) pretreated with polyethyleneimine. Ligand-binding analy-
sis with detergent-solubilized receptors was done in assay bu¡er con-
taining detergent (0.1% LM, 0.2% CHAPS, 0.04% CHS) [14,15] for 1 h
on ice. Separation of receptor^ligand complex from free ligand was
achieved by centrifugation-assisted gel ¢ltration using Bio-Spin 30
Tris columns (Bio-Rad) according to the manufacturer’s instructions.
Samples were analyzed by liquid scintillation counting.
3. Results and discussion
3.1. Large-scale fermentation
To provide the starting material for automated puri¢cation
of NTS1 fusion proteins on a regular basis, fermentation at a
200-l scale was carried out. [3H]NT ligand-binding analyses
with intact cells gave V1000 receptors/cell, a value compara-
ble to that obtained in shake £ask experiments [13^15]. The
cell density at harvest was 2.5^3 OD600. One 200-l run yielded
about 1.1 kg of wet bacterial cell paste with 90 mg of func-
tional receptor fusion protein (data are averaged from ¢ve
fermenter runs). Attempts to increase the biomass at harvest,
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by inducing expression at a cell density higher than OD600 of
0.5 or by using richer media, resulted in lower levels of func-
tional receptors per cell. The best results in expression and
puri¢cation of NTS1 fusion proteins were obtained by mim-
icking the growth conditions in shake £asks.
3.2. Automated puri¢cation
The preparation of GPCRs in functional form must be
reproducible to provide high-quality material for regular crys-
tallization experiments. A ‘manual’, two-step puri¢cation pro-
cedure, immobilized metal a⁄nity chromatography followed
by a NT column, has been shown to give functional, pure
NTS1 fusion protein [15] at small scale, and we have adapted
this procedure to the production of receptors in milligram
quantities [17]. However, the increased volumes of sample
and column bu¡ers, combined with slow £ow rates needed
Fig. 1. Schematic representation of the chromatography system used
for automated puri¢cation of NTS1 fusion proteins. Circles denote
valves (1, injection valve; 2, column valves; 3, outlet valve; 4, sam-
ple valve; 5, bu¡er valve A1; 6, bu¡er valve B2). The system pumps
are indicated as A and B. Bu¡er lines F3 and B22 are used to col-
lect and to load the Ni-NTA column eluate (NiE) onto the NT col-
umn. The NT column eluate (NTE) is collected by the fraction col-
lector. The composition of the bu¡ers NiA, NiB, NT0, NT200 and
NT1K are given in Section 2. For clarity, not all bu¡ers and bu¡er
lines are shown.
Table 1
Automated large-scale puri¢cation of the fusion protein NTS1^624
Volume (ml) Functional receptor (nmol) Protein (mg) Speci¢c binding (nmol/mg) Puri¢cation (fold) Recovery (%)
100 g of cells, 50-ml Ni-NTA column, 10-ml NT column
supernatant 478 82.8 5214 0.016 1 100
NiFT 548 11.8 ND ND NA 14
NiE 60 ND ND ND ND
NTFT 207 ND 4.9 ND NA
NTE 8 32.6 3.2 10.2 640 39
250 g of cells, 100-ml Ni-NTA column, 20-ml NT column
supernatant 934 193.5 13562 0.014 1 100
NiFT 1070 22.4 ND ND NA 12
NiE 122 145.5 30 4.8 345 75 (100)
NTFT 412 4.3 13 ND NA 2 (3)
NTE 14 103.8 9.6 10.8 774 53 (71)
Data for the 3-mg preparation are the average of four puri¢cations. Data for the 10-mg preparation are taken from one representative experi-
ment. NiFT contains the actual £owthrough and bu¡er used to wash the sample pump. The volume of the NTFT is larger than that of the
NiE because of the dilution applied to reduce the NaCl and imidazole concentrations. Recovery data listed in parentheses refer to the NT col-
umn. A theoretical value for speci¢c binding of 10.4 nmol/mg is calculated for NTS1^624 (molecular mass of 96.5 kDa) assuming one ligand-
binding site per receptor molecule. Abbreviations: NA, not applicable; ND, not determined; NiE, Ni-NTA column eluate; NiFT, £owthrough
of Ni-NTA column; NTE, NT column eluate; NTFT, £owthrough of NT column.
Fig. 2. Automated 10-mg preparation of the fusion protein NTS1^
624. The NTS1 fusion protein was puri¢ed on a 100-ml Ni-NTA
column followed by a 20-ml NT column, starting from 250 g of
cells. The progress of puri¢cation was monitored by SDS^PAGE
(NuPAGE 4^12% Bis-Tris gel, Invitrogen, 1UMES bu¡er) and
Coomassie R-250 staining. Lane M: Novagen Perfect Protein
Marker (15^150 kDa); lane 1: 10 Wg of supernatant; lane 2: 10 Wg
of Ni-NTA column £owthrough; lane 3: 5 Wg of Ni-NTA column
eluate; lane 4: 10 Wg of NT column £owthrough; lane 5: 5 Wg of
NT column eluate.
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to obtain high receptor yields, made this procedure impracti-
cal. Therefore, automation of sample loading and successive
processing of the two a⁄nity columns was desirable [18].
Fig. 1 shows the chromatography scheme for the automated
puri¢cation of NTS1 fusion proteins. The program routines
ensure that each bu¡er line, pump head and column are ¢lled
with the correct bu¡er at any given time. An air sensor detects
the end of sample loading, and initiates the Ni-NTA column
wash. The apparent capacity of the Ni-NTA resin in our bu¡-
er system is low (6 0.5 mg of NTS1 fusion protein/ml resin,
see Table 1), hence the use of large columns. The Ni-NTA
column eluate is collected in a vessel connected to a second air
sensor for loading of the NT column. However, the apparent
a⁄nity of NT for NTS1 is reduced in the presence of the high
concentrations of sodium ions and imidazole in the NiB bu¡er
[15] precluding binding of functional receptors to the NT col-
umn. The necessary change in bu¡er composition is accom-
plished by diluting the Ni-NTA column eluate with NT0 bu¡-
er just prior to loading of the NT column, using the system
pumps. After elution of receptors from the NT column and
collection, the columns are washed into storage bu¡er, and
the system pumps are cleaned with H2O and 20% ethanol.
Starting with solubilization, a 3-mg receptor preparation is
available after 31 h, whereas a 10-mg preparation is com-
pleted after 55 h. Fig. 2 and Table 1 detail the large-scale
puri¢cation of the fully functional receptor fusion protein
NTS1^624. Similar results at the 3-mg and 10-mg level have
been obtained for NTS1^1023 and NTS1^1233 (data not
shown).
3.3. Generation of rT43NTR
3.3.1. Identi¢cation of a cryptic Tev protease recognition site
at the C-terminus of NTS1. The puri¢ed fusion protein
NTS1^1023 with Tev protease recognition sites at either end
of rT43NTR was subjected to protease treatment, and the
proteolytic fragments were analyzed by sodium dodecyl sul-
fate^polyacrylamide gel electrophoresis (SDS^PAGE) (Fig. 3).
rT43NTR showed an apparent MW smaller than the calcu-
lated MW of 44.8 kDa. Unexpectedly, rT43NTR was found
Fig. 3. Identi¢cation of a cryptic Tev protease recognition site at
the C-terminus of NTS1. The fusion protein NTS1^1023 was puri-
¢ed by immobilized metal a⁄nity chromatography and a NT col-
umn, and incubated with Tev protease. The products were analyzed
by SDS^PAGE (NuPAGE 4^12% Bis-Tris gel, Invitrogen, 1UMES
bu¡er) and Coomassie R-250 staining. Lane M: Novagen Perfect
Protein Marker (15^150 kDa); lane 1: 6.6 Wg of Tev protease (cal-
culated MW=28.6 kDa); lane 2: 6.7 Wg of puri¢ed NTS1^1023
(calculated MW=100.9 kDa); lane 3: 12.5 Wg of the protein mix-
ture after incubation with Tev protease (calculated MW of
MBP=42.3 kDa, calculated MW of rT43NTR=44.8 kDa, calcu-
lated MW of TrxA-H10= 13.8 kDa). N-terminal sequence analysis
and in-gel tryptic digest followed by LC/MS/MS identi¢ed two re-
ceptor species with identical N-termini but di¡erent C-termini and
an apparent MW smaller than calculated.
Fig. 4. Puri¢cation of rT43NTR. NTS1^1233 was puri¢ed by immo-
bilized metal a⁄nity chromatography and a NT column, and incu-
bated with Tev protease. The resulting proteins were separated by
gel ¢ltration (A) and analyzed by SDS^PAGE (B) (NuPAGE
4^12% Bis-Tris gel, Invitrogen, 1UMES bu¡er) and Coomassie R-
250 staining. Lane M: Novagen Perfect Protein Marker (15^150
kDa); lane 1: 5 Wg of puri¢ed NTS1^1233; lane 2: 5 Wg of Tev
protease; lane 3: 12 Wg of the protein mixture after incubation with
Tev protease; lane 4: gel ¢ltration peak 1; lane 5: gel ¢ltration
peak 2, 5 Wg of rT43NTR (calculated MW=43.3 kDa); lane 6: gel
¢ltration peak 3, 5 Wg of protein (MBP, Tev protease); lane 7: gel
¢ltration peak 4, 5 Wg of TrxA-H10. Note that gel ¢ltration peak 1
contains hardly any protein.
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as two species. N-terminal sequence analysis and in-gel tryptic
digest followed by LC/MS/MS identi¢ed identical N-termini
for the two proteins. However, two di¡erent putative C-ter-
minal tryptic peptides were found (Glu-Thr-Leu-Tyr-Ala3-
Asn5-Gly3-Ser-Glu-Asn-Leu-Tyr-Phe-Gln and Glu-Thr-Leu-
Tyr-Ala-Ala, data not shown). The canonical Tev protease
recognition site is given as Glu-Asn-Leu-Tyr-Phe-GlnsGly/
Ser [24]. Three amino acid residues of the NTS1 C-terminus
(Glu, Leu, Tyr) are identical to the canonical Tev protease
recognition site. This receptor region is recognized by Tev
protease, although less e⁄ciently (the smaller receptor frag-
ment is less abundant, see Fig. 3).
3.3.2. Preparation of rT43NTR. To obtain a uniform re-
ceptor species, the sequence of the rT43NTR C-terminus was
changed from Glu421-Thr-Leu-Tyr424 to Glu421-Asn-Leu-Tyr-
Phe-Gln-Ser to constitute a canonical Tev protease recogni-
tion site. The correct processing by Tev protease of NTS1^
1233 was con¢rmed by in-gel tryptic digest and mass spec-
trometry (data not shown) with the receptor C-terminus end-
ing in Glu421-Asn-Leu-Tyr-Phe-Gln. The receptor was sepa-
rated from MBP, Tev protease and TrxA-H10 by gel ¢ltration
(Fig. 4) with a yield of 1.6 mg rT43NTR (69% of theoretical
recovery) starting from 5.4 mg of fusion protein. Similar re-
covery yields (70^80%) were obtained in three further experi-
ments (data not shown). Ligand-binding analysis gave a Bmax
value of 19.7 nmol/mg (a theoretical value for speci¢c binding
of 23.1 nmol/mg is calculated for rT43NTR (molecular mass
of 43.3 kDa) assuming one ligand-binding site per receptor
molecule) (data presented are from one representative experi-
ment). Careful inspection of the rT43NTR preparation
showed some minor contaminants originating from the Tev
protease preparation, which cannot easily be seen in Fig. 4.
Future optimization of the gel ¢ltration step is required to
remove these unwanted proteins.
4. Conclusions
The presented large-scale puri¢cation of NTS1 fusion pro-
teins is simple and robust. It reliably provides high-quality
receptor material for crystallization and other applications
such as antibody generation. Receptors are solubilized from
whole cells as starting material, rather than crude membranes,
which are time-consuming to prepare. The use of a H10 tag
allows the e⁄cient enrichment of receptors by immobilized
metal a⁄nity chromatography. The subsequent NT column
selects for functional protein. The use of air sensors and au-
tomated column processing minimizes the time needed for
puri¢cation.
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